An official website of the United States government

Publication Information

PubMed ID
Public Release Type
Journal
Publication Year
2021
Authors
Hopp Katharina, Catenacci Victoria A., Dwivedi Nidhi, Kline Timothy L., Wang Wei, You Zhiying, Nguyen Dustin T., Bing Kristen, Poudyal Bhavya, Johnson Ginger C., Jackman Matthew R., Miller Marsha, Steele Cortney N., Serkova Natalie J., MacLean Paul S., Nemenoff Raphael A., Gitomer Berenice, Chonchol Michel, Nowak Kristen L.
Studies

Abstract

Progression of autosomal dominant polycystic kidney disease (ADPKD) is modified by metabolic defects and obesity. Indeed, reduced food intake slows cyst growth in preclinical rodent studies. Here, we demonstrate the feasibility of daily caloric restriction (DCR) and intermittent fasting (IMF) in a cohort of overweight or obese patients with ADPKD. Clinically significant weight loss occurred with both DCR and IMF; however, weight loss was greater and adherence and tolerability were better with DCR. Further, slowed kidney growth correlated with body weight and visceral adiposity loss independent of dietary regimen. Similarly, we compared the therapeutic efficacy of DCR, IMF, and time restricted feeding (TRF) using an orthologous ADPKD mouse model. Only ADPKD animals on DCR lost significant weight and showed slowed cyst growth compared to ad libitum, IMF, or TRF feeding. Collectively, this supports therapeutic feasibility of caloric restriction in ADPKD, with potential efficacy benefits driven by weight loss.